Contrarian Investors: Don’t Expect a Sudden Rebound in Valeant Pharmaceuticals Intl Inc.

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) appears to be getting cheaper by the day. Is it finally time to initiate a contrarian position?

| More on:
The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is in the midst of a transformation overhaul as its new CEO Joseph Papa looks to clean up the mess that Michael Pearson and the old management team left behind. Valeant has lost almost 97% of its value as the stock continues to fall further into the abyss. Unfortunately for many contrarian investors, the stock continued its tumble into the single digits.

It’s undervalued, but is it safe to buy shares?

Many pundits believe that Valeant is extremely undervalued and that the company could offer contrarians the opportunity for a rebound of a lifetime. Valeant owns terrific core assets, but the fire sale of non-core assets is far from over, as the management team looks to raise money to chip away at the mountain of debt.

I think Valeant is close to a bottom, but if you’re hungry for a rebound, you’ve got to be realistic. Valeant probably isn’t going to skyrocket overnight or quadruple over the next three years as some of the more bullish analysts out there believe. If you’re got a stomach for volatility and you can afford to wait five years or more, then Valeant could be an intriguing rebound play. Bill Ackman had horrible timing when he first initiated a position. And maybe his decision to dump the stock was just as poorly timed.

Valeant recently released the first real positive piece of news in a long time. The company raised its full-year adjusted EBITDA forecast, and the company is on schedule to reach its target of paying back $5 billion in debt by February 2018. This is promising news, and I believe the rally that followed was completely warranted.

Where is the stock heading from here?

The rally has since run out of steam, and Valeant appears to be picking up negative momentum again. There’s a stigma surrounding Valeant which I don’t think will go away with a new management team. The possibility of a company name change was also brought up, but would this attract investors? Or is it just a cheap trick that investors will see through?

I’m not sure, but it appears that Valeant will require a steady stream of good news to keep the stock moving higher; otherwise, in the short to medium term, I think the stock will continue to decline by default.

I’m a huge fan of the core assets owned by Valeant, and I believe they are absurdly undervalued, but I think it’ll take many years to attract investors back to the company and its new, legitimate business model.

I would recommend picking up shares in very small increments on the way down, but only if you truly believe in Joseph Papa and the new management team. I think he’s the right man for the job, but keep in mind, he’s not a miracle worker. There’s still a lot of cleaning up to do, and a sustainable rally may be a year or more away.

Stay smart. Stay hungry. Stay Foolish.

Fool contributor Joey Frenette has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

woman stares at chocolate layer cake
Dividend Stocks

Why Smart Investors Are Eyeing These 3 Canadian Stocks Right Now

These three TSX picks offer real assets and clear catalysts, without needing a perfect market to work.

Read more »

Income and growth financial chart
Stocks for Beginners

This Stock, Up Over 306% in 10 Years, Looks Like a Genius Buy Right Now

Brookfield stock appears to be a genius buy for long-term investors, particularly on market dips.

Read more »

Person holds banknotes of Canadian dollars
Retirement

How to Build a Retirement Portfolio That Generates $2,000 a Month

Are you wondering how you could earn $2,000 of passive income for retirement? These two different approaches could get you…

Read more »

Couple working on laptops at home and fist bumping
Dividend Stocks

The Canadian Stocks I’d Prioritize if I Had $5,000 to Invest Right Now

These two TSX stocks offer a good combo of growth and stable income, making them excellent picks to consider for…

Read more »

dividend stocks are a good way to earn passive income
Dividend Stocks

Today’s Perfect TFSA Stock: 6% Monthly Income

SmartCentres REIT stands out as the perfect TFSA stock for Canadians seeking reliable monthly income, and long‑term stability.

Read more »

A modern office building detail
Dividend Stocks

2 Canadian REITs That Look Worth Buying Right Now

SmartCentres REIT (TSX:SRU.UN) and another yield-rich, passive-income play are fit for Canadian value seekers.

Read more »

man looks surprised at investment growth
Investing

3 Canadian Stocks That Look Undervalued and Worth Buying Right Now

These high-quality Canadian stocks still look undervalued and are well-positioned to deliver notable growth in the future.

Read more »

dividends grow over time
Investing

3 Canadian Growth Stocks Worth Adding to a TFSA This Year

Three Canadian growth stocks are valuable additions to the TFSA for investors prioritizing capital gains over dividend income in 2026.

Read more »